Paddy Power will continue to fund Prostate Cancer UK and support British darts through 2031 thanks to its latest title sponsorship extension.

Netflix (NFLX +1.66%) announced some exciting news recently: It's enacting a 10-for-1 forward stock split, effective on Nov. 17. Stock splits can be exciting for investors for multiple reasons, ...

Benson Kipruto won the men’s race by three-hundredths of a second, and Hellen Obiri won the women’s race, obliterating the course record by more than two minutes. Scott Cacciola The five boroughs of ...

GitHubHero is a Dockerized Python app using FastAPI, Streamlit, and Plotly to analyze and display your language trends and contributions via GitHub GraphQL API This repository serve as a reference ...

Gov. Gavin Newsom signed a bill to regulate data centers but vetoed another as California looks to balance protecting consumers with jump-starting its lagging digital infrastructure sector. California ...

Hello guys, I am working on creating a Monitoring using Azure ML mainly for checking the Data Quality signal (Quality of the baseline and production data) and Data Drift signal (Change in distribution ...

The U.S. labor market’s weakening backdrop drove the Fed to cut interest rates by a quarter percentage point on Sept. 17, the first policy easing of 2025. That’s after employers added just 22,000 jobs ...

With seven arcs and two directions, the biggest clue in the MH370 case sparked a global debate. Trump wants to ‘end’ largest US infrastructure project, a tunnel between NY and NJ ‘We Reject That’: ...

Abstract: Split learning (SL) aims to protect user data privacy by distributing deep models between the client-server and keeping private data locally. In SL training with multiple clients, the local ...

An MMA fighter puked near the UFC Fight Pass logo in the cage—twice. UFC Abu Dhabi went down on Saturday but this weekend’s fights weren’t over just yet. Fury Challenger Series 14 took place on Sunday ...

(RTTNews) - Gilead Sciences, Inc. (GILD) Monday announced that Gilead researchers and collaborators will present new Phase 3 Purpose trial data at IAS 2025 showing that twice-yearly lenacapavir ...